Our lead TCR-T therapy candidate, TSC-101, is in development for the treatment of patients with hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (the Phase 1 ALLOHA™ trial, NCT05473910). TSC-101 is administered after allogeneic bone marrow transplantation (hematopoietic cell transplantation or HCT) and has been designed to target residual disease and prevent relapse post-HCT. The Company has also developed multiple TCR-T cell therapy candidates for the treatment of solid tumors and is currently engaged in preclinical development of in vivo-engineered T cells using these TCRs.

TScan was founded in early 2018 to discover and develop TCR-T therapies using a novel target discovery platform. Over the years, we have used this technology to understand how T cells naturally recognize and fight cancer and have leveraged this information to build a broad pipeline of TCR-T therapy candidates. We have also used this technology to understand how T cells aberrantly cause or contribute to autoimmune disorders and are actively discovering novel autoantigens to enable the development of targeted therapeutics.

Meet our expert management team.